Refractory Primary Malignant Central Nervous System Neoplasm

Explore clinical trials studying Refractory Primary Malignant Central Nervous System Neoplasm. Study availability and eligibility vary by location and protocol.

4 public trials 1 recruiting study

Refine in advanced search Browse all conditions

Refractory Primary Malignant Central Nervous System Neoplasm trial results

Recruiting

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

NCT04870944

Conditions: Brain Diseases, Brain Neoplasms, Brain Stem Neoplasms, +31 more
Locations: Children's Hospital of Alabama Birmingham, Alabama, United States

Phoenix Childrens Hospital Phoenix, Arizona, United States

Children's Hospital Los Angeles Los Angeles, California, United States

Children's Hospital of Orange County Orange, California, United States

View all 35 locations

View Trial Details

Active, Not Recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

NCT02867592

Conditions: Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +92 more
Locations: Children's Hospital of Alabama Birmingham, Alabama, United States

Providence Alaska Medical Center Anchorage, Alaska, United States

Arkansas Children's Hospital Little Rock, Arkansas, United States

Kaiser Permanente-Anaheim Anaheim, California, United States

View all 142 locations

View Trial Details

Active, Not Recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

NCT03698994

Conditions: Advanced Malignant Solid Neoplasm, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, +83 more
Locations: Children's Hospital of Alabama Birmingham, Alabama, United States

Providence Alaska Medical Center Anchorage, Alaska, United States

Banner Children's at Desert Mesa, Arizona, United States

Banner University Medical Center - Tucson Tucson, Arizona, United States

View all 107 locations

View Trial Details

Active, Not Recruiting

Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors

NCT05768880

Conditions: Brain Diseases, Brain Neoplasms, Brain Stem Neoplasms, +23 more
Locations: Seattle Children's Hospital Seattle, Washington, United States

View Trial Details

Refractory Primary Malignant Central Nervous System Neoplasm

Refractory Primary Malignant Central Nervous System Neoplasm trial results

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors

Related conditions